Anticoagulation in special patient populations: are special dosing considerations required?

Authors

• Franklin Michota
• Geno Merli

Publication/Presentation Date

4-1-2005

Abstract

Optimal dosing of low-molecular-weight heparin (LMWH) therapy has not yet been established for patients with morbid obesity or renal insufficiency or for pregnant women. Monitoring of anti-Xa levels appears to be helpful in guiding LMWH dosing in all of these patient groups. Use of fondaparinux in these populations has yet to be defined. Cancer patients are at particular risk of venous thromboembolism and generally require escalated and/or prolonged anticoagulation with intense monitoring of therapy.

Volume

72 Suppl 1

First Page

37

Last Page

42

ISSN

0891-1150

Published In/Presented At

Michota, F., & Merli, G. (2005). Anticoagulation in special patient populations: are special dosing considerations required?. Cleveland Clinic journal of medicine, 72 Suppl 1, S37–S42. https://doi.org/10.3949/ccjm.72.suppl_1.s37

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

15853178

Department(s)

Administration and Leadership

Document Type

Article